PDF(Pubmed)
Abstract：
The goal was to explore the effect of interleukin-6 (IL6) and C reactive protein (CRP) on malignant melanoma (MM) using two-sample Mendelian randomization.
UNASSIGNED: Data for this study were obtained from the IEU Open GWAS project website for genome-wide association study data (GWAS) on interleukin-6, C reactive protein levels and malignant melanoma. Inverse variance weighted (IVW) method was mainly used and supplemented with MR-Egger regression and weighted median. Finally, horizontal multivariate validity and heterogeneity tests were performed to assess the stability and reliability of the results.
UNASSIGNED: The results of univariate two-sample MR analyses showed no significant effect of CRP on MM: inverse variance weighting method (OR=0.999, 95% CI: 0.998-1.001, P=0.343), MR-Egger regression (OR= 1.000, 95% CI: 0.998-1.001, P= 0.180), and weighted median method (OR= 0.999, 95% CI: 0.997 to 1.000, P= 0.583), and weighted model (OR= 0.999, 95% CI: 0.998 to 1.001, P= 0.328). Also,IL-6 had no significant effect on MM: inverse variance weighting method (OR= 1.001, 95% CI: 0.999 to 1.002, P=0.461), MR-Egger regression (OR= 1.000, 95% CI: 0.997 to 1.004, P= 0.910), weighted median method (OR= 1.000, 95% CI: 0.998 to 1.002, P= 0.749), and weighted mode (OR= 1.000, 95% CI: 0.998 to 1.002, P= 0.820).
UNASSIGNED: There was no causal relationship between C-reactive protein and IL-6 on the risk of malignant melanoma.
UNASSIGNED: Data for this study were obtained from the IEU Open GWAS project website for genome-wide association study data (GWAS) on interleukin-6, C reactive protein levels and malignant melanoma. Inverse variance weighted (IVW) method was mainly used and supplemented with MR-Egger regression and weighted median. Finally, horizontal multivariate validity and heterogeneity tests were performed to assess the stability and reliability of the results.
UNASSIGNED: The results of univariate two-sample MR analyses showed no significant effect of CRP on MM: inverse variance weighting method (OR=0.999, 95% CI: 0.998-1.001, P=0.343), MR-Egger regression (OR= 1.000, 95% CI: 0.998-1.001, P= 0.180), and weighted median method (OR= 0.999, 95% CI: 0.997 to 1.000, P= 0.583), and weighted model (OR= 0.999, 95% CI: 0.998 to 1.001, P= 0.328). Also,IL-6 had no significant effect on MM: inverse variance weighting method (OR= 1.001, 95% CI: 0.999 to 1.002, P=0.461), MR-Egger regression (OR= 1.000, 95% CI: 0.997 to 1.004, P= 0.910), weighted median method (OR= 1.000, 95% CI: 0.998 to 1.002, P= 0.749), and weighted mode (OR= 1.000, 95% CI: 0.998 to 1.002, P= 0.820).
UNASSIGNED: There was no causal relationship between C-reactive protein and IL-6 on the risk of malignant melanoma.
摘要：
目的是使用孟德尔随机双样本研究白细胞介素6（IL6）和C反应蛋白（CRP）对恶性黑色素瘤（MM）的影响。
■本研究的数据来自IEUOpenGWAS项目网站，用于获得白细胞介素6，C反应蛋白水平和恶性黑色素瘤的全基因组关联研究数据（GWAS）。主要采用逆方差加权(IVW)法,辅以MR-Egger回归和加权中位数。最后,采用水平多变量效度和异质性检验来评估结果的稳定性和可靠性.
■单变量双样本MR分析结果显示CRP对MM无显著影响：方差逆加权法（OR=0.999，95%CI：0.998-1.001，P=0.343），MR-Egger回归(OR=1.000,95%CI:0.998-1.001,P=0.180),加权中位数法(OR=0.999,95%CI:0.997~1.000,P=0.583),加权模型(OR=0.999,95%CI:0.998~1.001,P=0.328)。此外，IL-6对MM无显著影响:方差反加权法(OR=1.001,95%CI:0.999~1.002,P=0.461),MR-Egger回归(OR=1.000,95%CI:0.997~1.004,P=0.910),加权中位数法(OR=1.000，95%CI：0.998~1.002，P=0.749)，加权模式(OR=1.000,95%CI:0.998~1.002,P=0.820)。
■C反应蛋白和IL-6与恶性黑色素瘤的风险之间没有因果关系。
■本研究的数据来自IEUOpenGWAS项目网站，用于获得白细胞介素6，C反应蛋白水平和恶性黑色素瘤的全基因组关联研究数据（GWAS）。主要采用逆方差加权(IVW)法,辅以MR-Egger回归和加权中位数。最后,采用水平多变量效度和异质性检验来评估结果的稳定性和可靠性.
■单变量双样本MR分析结果显示CRP对MM无显著影响：方差逆加权法（OR=0.999，95%CI：0.998-1.001，P=0.343），MR-Egger回归(OR=1.000,95%CI:0.998-1.001,P=0.180),加权中位数法(OR=0.999,95%CI:0.997~1.000,P=0.583),加权模型(OR=0.999,95%CI:0.998~1.001,P=0.328)。此外，IL-6对MM无显著影响:方差反加权法(OR=1.001,95%CI:0.999~1.002,P=0.461),MR-Egger回归(OR=1.000,95%CI:0.997~1.004,P=0.910),加权中位数法(OR=1.000，95%CI：0.998~1.002，P=0.749)，加权模式(OR=1.000,95%CI:0.998~1.002,P=0.820)。
■C反应蛋白和IL-6与恶性黑色素瘤的风险之间没有因果关系。
